Alrizomadlin is under clinical development by Ascentage Pharma Group International and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Alrizomadlin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Alrizomadlin overview

Alrizomadlin (APG-115) is under development for the treatment of solid tumors, neuroblastoma,  relapsed/refractory T-cell prolymphocytic leukemia, soft tissue sarcoma, adenoid cystic carcinoma, uveal melanoma, osteosarcoma, liposarcoma, salivary gland cancer, relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, relapsed/ refractory chronic myelomonocytic leukemia (CMML), peripheral nerve sheath tumor, acute myelocytic leukemia (AML), gastric cancer and metastatic melanoma. It is administered orally. The drug candidate is a new chemical entity. It acts by targeting MDM2-p53. It is a small-molecule mouse double minute 2 homolog (MDM2) inhibitor. It was also under development for the treatment of dry age related macular degeneration,  adenoid cystic carcinoma (ACC) and sarcoma.

It was also under development of the treatment of lymphomas, non-small cell lung cancer, urothelial cancer.

Ascentage Pharma Group International overview

Ascentage Pharma Group International (Ascentage Pharma) is a biotechnology company that discovers and develops targeted small-molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company product pipeline includes HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma lead candidate HQP8361 is a second-generation c-Met kinase inhibitor for the treatment of c-Met positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. It operates research and development centers and production facilities in Hong Kong, China, and the US. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.

For a complete picture of Alrizomadlin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.